vVARDIS (VVVV) IPO Prices at $18, Raising $175 Million on the NYSE
As seen on the 24/7 Wall St. homepage on November 16, 2026.
Priced at $18, raising about $175 million
Priced at $18 a share for roughly $175 million, giving the Swiss enamel-regeneration company one of the larger medtech debuts to clear the NYSE this year. Goldman Sachs, J.P. Morgan, UBS, Deutsche Bank and William Blair all ran the book, a syndicate that size signals real institutional demand. First trade sets the tone for the listings queued behind it.
Continue ReadingShow less
vVARDIS Holding AG, a Swiss company focused on enamel regeneration, priced its shares at $18 each, raising roughly $175 million in one of the larger medtech debuts to hit the NYSE this year. The deal covered 9,722,223 shares, giving the offering real scale for a company in this space.
The syndicate running the book included Goldman Sachs, J.P. Morgan, UBS, Deutsche Bank, and William Blair. Five banks of that caliber committing to a single deal is a signal of serious institutional appetite: underwriters of that standing do not assemble for offerings they expect to struggle.
Sponsored
For investors watching the medtech IPO calendar, the first trade out of the gate carries weight beyond vVARDIS itself. A clean open at or above the $18 offer price would give the listings queued behind it a cleaner runway; a stumble would tighten conditions for the whole cohort.
The enamel-regeneration category sits at the intersection of dentistry and biotech, a niche drawing growing attention from consumers and clinicians seeking restorative solutions. How institutional holders who took allocations choose to trade in the first sessions will indicate whether the $18 pricing reflects genuine conviction or simply cleared the bar.
Mentioned: VVVV